Biogen Reports Phase 2b Data for Tofacitinib in Multiple sclerosis

Biogen today announced Phase 2b results for tofacitinib in patients with multiple sclerosis. The study demonstrated that tofacitinib improves functional outcomes compared to standard of care or placebo. These results provide important insights into the treatment of multiple sclerosis and support the continued development of tofacitinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.